Latest Content

VCN-01 plus standard chemotherapy and Abraxane proved safe and effective for patients with metastatic pancreatic cancer.

Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.

Alecensa achieved a 98.4% 4-year overall survival rate versus 92.4% with chemotherapy in resected ALK-positive early-stage lung cancer.

Trodelvy plus Keytruda may maintain quality of life and slow physical decline in metastatic triple-negative breast cancer.

Antibody-drug conjugate treatment rates increased 3.7-fold from 2021 to 2023 for patients with metastatic breast cancer.

The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free survival.

Enhertu plus Perjeta improved progression-free survival versus THP in patients with HER2-positive advanced or metastatic breast cancer across subgroups.

After her follicular lymphoma diagnosis, Karen Cohn reflects on how cancer reshaped her view of mortality and her choice to keep living fully.

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show.

Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.

Loqtorzi improved progression-free and overall survival versus chemotherapy in HER2-expressing advanced urothelial cancer.

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.